Mutation of the SOX2 binding site in the SLC7A11 promoter enhances cancer cell sensitivity to ferroptosis, proposing SLC7A11 as a potential therapeutic target for lung cancer treatment (Wang et al., 2021c). This evidence concerns the gene SLC7A11 and lung cancer.